designed a nanoplatform delivery system from porous hollow iron oxide nanoparticles (PHNPs) and carbonylated mannose for targeting delivery of PI3Kγ small molecule inhibitor (3‐methyladenine, 3‐MA).[151] The resultant nanoparticles (PHNPs@DPA‐S‐S‐BSA‐MA@3‐MA) could effectively target M2‐like TAMs and reverse them into anti‐tumor M1 phenotype by inhibiting PI3Kγ expression, accompanied with up‐regulation of NF‐κB p65 protein. This evidence concerns the gene NFKB1 and neoplasm.